论文部分内容阅读
2011年7月26日(FDA发布)美国食品药品管理局(FDA)收到报告称,服用作用于5一羟色胺系统的精神病药物的患者用利奈唑胺,可产生严重中枢神经系统反应。利奈唑胺是一种可逆的单胺氧化酶抑制剂。虽然该药确切的相互作用机制尚未明确,但利奈唑胺有抑制单胺氧化酶A(一种分解脑内5一羟色胺的物质)的作用。有理由相信利奈唑胺应用于使用5-羟色胺类精神病药物的患者时,脑内5一羟色胺水平升高,引致5一羟色胺综合征。症状和体征包括精神异常(意识模糊、亢奋、记忆障碍)、肌肉痉挛、大汗淋漓、颤抖或晃动、腹泻、共济失调和(或)发热。
July 26, 2011 (FDA Release) The U.S. Food and Drug Administration (FDA) has received reports that patients receiving mitoxantrone as a psychotropic drug for the serotonin 5 system produce severe central nervous system reactions. Linezolid is a reversible monoamine oxidase inhibitor. Although the exact mechanism of interaction of this drug is not clear, linezolid has the effect of inhibiting monoamine oxidase A, a substance that breaks down serotonin in the brain. When there is reason to believe that linezolid is used in patients with serotonin-type psychosis, elevated levels of serotonin 5 in the brain cause 5-HT syndrome. Symptoms and signs include mental disorders (confusion, hyperkinesia, memory impairment), muscle cramps, sweating, trembling or shaking, diarrhea, ataxia and / or fever.